Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Tumors were resected from mice 10 days after orthotopic inoculation of 4T1-Luc2 cells, and hydrogels loaded with the following payloads were evaluated: anti–PD-1, anti-CTLA-4, IL-15sa, lenalidomide, celecoxib, STING-RR, or R848. Mice that did not receive a hydrogel were examined as a negative control. (A) IVIS imaging of 4T1-Luc2 cells is shown for all groups described and illustrates tumor burden.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Celecoxib purchased from Selleck.

    Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

  • Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

    Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

  • Oncol Lett, 2018, 16(1):317-325. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MVHGeY5kfGmxbjDBd5NigQ>? NFTFfIUxNjFvM{Cg{txO NXnoWmIxPDhiaB?= MVvpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> MXOyOlUyOzF5Mh?=
H460 NEnqU21HfW6ldHnvckBCe3OjeR?= NWjzelZqOC5zLUOwJO69VQ>? M2G1NVQ5KGh? MYPpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> NV;LZ5JnOjZ3MUOxO|I>
HKESC-2 NVLxZ4JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\Hb3p1OjEEoN88US=> MkjGOFjDqGkEoB?= MWrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> NUnaS2RLOjZ2N{S2PVM>
CaES-17 M2f4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGyTVlTOjEEoN88US=> MW[0POKhcMLi NIDaWm9{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? MomzNlY1PzR4OUO=
HKESC-2 NVPwSGxpSXCxcITvd4l{KEG|c3H5 NWHHO2ZROjEEoN88US=> Mmi5OFjDqGkEoB?= M1TuRZJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MVmyOlQ4PDZ7Mx?=
CaES-17 M2j6WGFxd3C2b4Ppd{BCe3OjeR?= NULFOlZ5OjEEoN88US=> NGLpe3Q1QMLiaNMg MlzvdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NF7KPJYzPjR5NE[5Ny=>
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HaSFUuOTZyIN88US=> NWGxdlZrPDkEoHlCpC=> Mn;6SG1UVw>? MkfCTWM2OD1zNkOuOEDPxE1? NHnZbWkzPjR4NE[0Ny=>
HCC827 NXvaZpNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjCOU0yPjBizszN NIfvfGY1QMLiaNMg MmnZSG1UVw>? NFvMT|hKSzVyPU[5MlIh|ryP NF7Kd2YzPjR4NE[0Ny=>
A549 MU\BdI9xfG:|aYOgRZN{[Xl? M3qw[lgxKML3TR?= NULJeFdLPDkEoHlCpC=> Ml6ySG1UVw>? MYnpcoR2[2W|IHHwc5B1d3Orcx?= Mlv0NlY1PjR4NEO=
HCC827 MkPRRZBweHSxc3nzJGF{e2G7 MlG4PFAhyrWP NE\zU281QMLiaNMg MnXCSG1UVw>? M4Cydolv\HWlZYOgZZBweHSxc3nz NGPIOoozPjR4NE[0Ny=>
SGC-7901/DDP NYnidHFwTnWwY4Tpc44hSXO|YYm= MnHrNVDDqML3TR?= NU\Dd|M{OjRiaB?= NEeyVnFqdmirYnn0d{BkgWOub3;4fYdmdmG|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v MmmzNlY1ODd4NUO=
SGC-7901  NFPLTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvaSnMzPMLiaNMg MVvJR|UxRTFzNT6wPEDPxE1? MVGyOlQxPzZ3Mx?=
SGC-7901/DDP NWK5UY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVeyOOKhcMLi NWjBeJkxUUN3ME2zOU41PSEQvF2= NES4NpYzPjRyN{[1Ny=>
SGC-7901/DDP NEm3[ZRCeG:ydH;zbZMhSXO|YYm= NHzVUIMyOMLiwsXN NY\pWG97OjRiaB?= M1HJfYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4> M{[5dVI3PDB5NkWz
SGC-7901/DDP MWfGeY5kfGmxbjDBd5NigQ>? NVvQOYdzOTEEoNM1US=> MUCyOEBp NYjkVYE2cW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= NWHmWos4OjZ2MEe2OVM>
SGC-7901/DDP MY\GeY5kfGmxbjDBd5NigQ>? NGDBRVkyOMLiwsXN M3jtb|I1KGh? NY\Cd|Bm[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv MWGyOlQxPzZ3Mx?=
H357 NIPScGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHEO{42NzFyIN88US=> NY[2cllKPDhiaB?= M1jtTGROW09? NUnNfFhxcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>? MUeyOlAxQTh5NB?=
TAF NVHsXFJkTnWwY4Tpc44hSXO|YYm= M4\4cVExyqEEtV2= MUC3JIQ> MVLh[oZm[3S|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>? MYqyOVk5PzF{Nx?=
TAF NUTSXW9mTnWwY4Tpc44hSXO|YYm= M{\6NFExyqEEtV2= M{jsVVMxNTF{MDDtbY4> M3nDcZBwd3KueTDh[oZm[3S|IHTBb5QheGixc4Doc5J6dGG2aX;uJINwdnOncYXlcpQhfG9iRVfGJJNq\26jbHnu[y=> NVzOZYZQOjV7OEexNlc>
TAF Ml3GSpVv[3Srb36gRZN{[Xl? NFnMTosyOMLiwsXN M2XpNlQ5KGh? NGTwcZZqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MorZNlU6QDdzMke=
PANC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofoNlAwPjBxMUCwJO69VQ>? NXL3PJRnOjRxNEivO|IhcA>? MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUOyOVk4OzB4Mh?=
PANC-1 MoXRSpVv[3Srb36gRZN{[Xl? NIfw[28zOC94MD:xNFAh|ryP NW\tb2FpOjRiaB?= M1HnOIF1fGWwdXH0d{Bk\WyuIHnueoF{cW:wIHHu[EBucWe{YYTpc44hcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXeyOVk4OzB4Mh?=
HeLa  NIDEc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOyc3gzOMLizszNxsA> NGr6WmQzPMLiaB?= MVnlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MVOyOVc4ODR{Mx?=
SACC-83 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyyNOKh|ryPwrC= NEexOlMzPMLiaB?= MWLlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MkSyNlU4PzB2MkO=
HeLa  M{TCb2Fxd3C2b4Ppd{BCe3OjeR?= MUSyNOKh|ryPwrC= NYq3SpoyOjUEoHi= M3XaSYVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> NF[xfZgzPTd5MESyNy=>
SACC-83 M3HmdmFxd3C2b4Ppd{BCe3OjeR?= NUizd2wxOjEEoN88UeKh MWOyOOKhcA>? NGrXVZlmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ NUny[5dMOjV5N{C0NlM>
HeLa  MWDGeY5kfGmxbjDBd5NigQ>? NFXIZVUzOC92MD:4NEDPxE1? MoTCNlTDqGh? M2LUepVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV NYHz[|IyOjV5N{C0NlM>
SACC-83 M2LsdWZ2dmO2aX;uJGF{e2G7 NXjGcZdCOjBxNECvPFAh|ryP MmjFNlTDqGh? NFfLXFd2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? NFq5SXkzPTd5MESyNy=>
HLCZ01 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\CdW54OOLCk{[wxsDDvU1? MlPkOFghcA>? MUnEUXNQ NGfHPJFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NYP0eJlZOjV5MkS4PVk>
HLCZ01 NWfWbpBsTnWwY4Tpc44hSXO|YYm= MlHoOFDDqM7:TR?= MUiyOEBp MVXEUXNQ M1rDfYlv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NWjx[lNROjV5MkS4PVk>
HLCZ01 NIm3c|BCeG:ydH;zbZMhSXO|YYm= M{G0WFQxyqEQvF2= M1jYflI1KGh? NUXrPZdRTE2VTx?= NFLFWZVmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u|rF? M{T1PFI2PzJ2OEm5
HLCZ01 NFTs[W5HfW6ldHnvckBCe3OjeR?= M2ntXlQxyqEQvF2= MVSyOEBp NYfJbJd{TE2VTx?= M12yN4lv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> M3LJVVI2PzJ2OEm5
MGC803 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjhT2QxNTZyIN88US=> M2HEfFczKGh? M4nEdGlEPTB;NEeuNlXjiIoEsfMAjVYvPDNizszN NWTsNJJsOjV5MEGzO|g>
SGC7901 M4PrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViwMVYxKM7:TR?= NVGxcnk3PzJiaB?= MVLJR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= M1izNVI2PzBzM{e4
MGC803 M4rBbmZ2dmO2aX;uJGF{e2G7 MVu0NOKh|ryP MWG4M|E3NzJ2IHi= M1jYbZVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> M124UVI2PzBzM{e4
SGC7901 MYDGeY5kfGmxbjDBd5NigQ>? M37Ie|QxyqEQvF2= NEHYe|I5NzF4L{K0JIg> NXT3S|V7fXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v Mm\BNlU4ODF|N{i=
MCF-7  NYfJN5plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUixM|ExKM7:TR?= NWHZfmFbPzJiaB?= M2fvNmROW09? MnXn[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NI\aeokzPTZ4N{WxNC=>
MDA-MB-231  MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjGRnYyNzFyIN88US=> MkC4O|IhcA>? NVXKUm1ETE2VTx?= NE\IcIhmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= NULUOFE1OjV4Nke1NVA>
MDA-MB-231 NYPN[49DTnWwY4Tpc44hSXO|YYm= NVe5d5RIOC12MDFCuW0> NWf6VFhGPC1{NDDo NWnDXVZJcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXGyOVU5PzN{OR?=
MCF-7 NUnOb|I{TnWwY4Tpc44hSXO|YYm= NV3JTmJrOC12MDFCuW0> MWq0MVI1KGh? MYDlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh MoXRNlU2QDd|Mkm=
MCF7-MX  MYPGeY5kfGmxbjDBd5NigQ>? M2LMO|AuPDBiwsXN M1q3d|QuOjRiaB?= NIjheVNmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi MUWyOVU5PzN{OR?=
MDA-MB-231 NXnTR3d3TnWwY4Tpc44hSXO|YYm= NHLFcYQxNTRyINM1US=> NYHGNnRzPC1{NDDo NWGweGZQe3SrbYXsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCDQlPHNkB2eCC2bzC0MlI4KHSrbXXzJJRwKGOxboTyc4whdGW4ZXygZpkhOTJiaNMg Mnr4NlU2QDd|Mkm=
A2780 Mnf0SpVv[3Srb36gRZN{[Xl? M{TyRlUwOTBxMUWg{txO NX3UWJFWPDhiaB?= MV3k[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkLQNlU1OjR6OUi=
SKOV3  M2XxWGZ2dmO2aX;uJGF{e2G7 MmnpOU8yOC9zNTFOwG0> NFeyN4c1QCCq M3ixbIRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{fGfVI2PDJ2OEm4
A2780 Ml7vSpVv[3Srb36gRZN{[Xl? Mlv4OU8yOC9zNTFOwG0> NXW4OY1WPDhiaB?= NFi2WVJmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw M3LXOlI2PDJ2OEm4
SKOV3  NHmwVHZHfW6ldHnvckBCe3OjeR?= NUnVRldGPS9zMD:xOUDPxE1? M3LsVVQ5KGh? Mkiz[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? MV2yOVQzPDh7OB?=
A2780 M3mzSWZ2dmO2aX;uJGF{e2G7 NX\QVXc3PS9zMD:xOUDPxE1? MXW0PEBp NYjQRW06\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu Mn;ONlU1OjR6OUi=
SKOV3  MnvHSpVv[3Srb36gRZN{[Xl? MX61M|ExNzF3IN88US=> NUTZN5o2PDhiaB?= NWC0S4xs\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu NHXtNnYzPTR{NEi5PC=>
A2780 NE\DcXhHfW6ldHnvckBCe3OjeR?= NV;EVo5LPS9zMD:xOUDPxE1? MonZNUBp Mo\SbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHzqVJgzPTR{NEi5PC=>
SKOV3  NIHrWGhHfW6ldHnvckBCe3OjeR?= NGGx[|g2NzFyL{G1JO69VQ>? NXHPW29oOSCq MkTybY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWDrRW9iOjV2MkS4PVg>
HCT-15 MWPGeY5kfGmxbjDBd5NigQ>? M{K5UVExNTVyIN88US=> M3zOVFYuOzZiaB?= M1LSdYlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NIDMe|UzPTJzOECyPC=>
HT-29  MWnGeY5kfGmxbjDBd5NigQ>? MVmxNE02OCEQvF2= NIrFRlU3NTN4IHi= NHHqO3BqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NFfkfo4zPTJzOECyPC=>
HSC3  NFW5O|RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MViw5qCUPDBizszN NW\Y[G5uPDhiaB?= MXzJR|UxRTJ3LkZCtVEvPzhyIN88US=> MWGyOVE6QDd6OR?=
HSC3  M2XKRWFxd3C2b4Ppd{BCe3OjeR?= MYCyOUDPxE1? Mof4OFghcA>? Ml;EbY5lfWOnczDhdI9xfG:|aYO= MV2yOVE6QDd6OR?=
HSC3  NG\xUohHfW6ldHnvckBCe3OjeR?= NY\6SGVwOjVizszN NHHhXlY1QCCq M{jHdYV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? M1W5dFI2OTl6N{i5
HSC3  M1TxfWZ2dmO2aX;uJGF{e2G7 MnfPNlUh|ryP MWi0PEBp MXrpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= NYOxOoY{OjVzOUi3PFk>
HSC3  NXLv[JRmTnWwY4Tpc44hSXO|YYm= NYnXZ|EzOjVizszN M{CxSlczKGh? NWG4SHNO\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh NH3IUmczPTF7OEe4PS=>
201T  NHf0U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjzWZpIPzJiaB?= MUXEUXNQ MYHJR|UxRTR6Lk[gxtVO M37RNlI2ODV5OUSx
273T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TROlczKGh? NU\X[XdJTE2VTx?= MYjJR|UxRThyLkWgxtVO MnzKNlUxPTd7NEG=
Hep-2 NVTodZhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLKU3Y{OC93MD:xNFAh|ryP NXLjWWRUOTJxMkSvN|YwPDhiaB?= NV3YSIF[TE2VTx?= Ml7KbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHPTfJgzPDl7OEW2OC=>
Hep-2 NET5[HJCeG:ydH;zbZMhSXO|YYm= NUS2fpNHPTBizszN NX;UfJdsOC12ODDo M3G0VWROW09? MXvpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NEjFWVYzPDl7OEW2OC=>
Hep-2 NXXlZpdPTnWwY4Tpc44hSXO|YYm= MYi1NEDPxE1? M1vwR|AuPDhiaB?= M1OzOWROW09? MWjy[YR2[2W|IITo[UB1\WyxbXXyZZNmKGGldHn2bZR6KGe{YXT1ZYxtgQ>? MYWyOFk6QDV4NB?=
Hep-2 NWTRXXBrTnWwY4Tpc44hSXO|YYm= NWXsSHduPTBizszN NXHrV|JkOC12ODDo MWLEUXNQ NEThZ2ll\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>? MWmyOFk6QDV4NB?=
SGC-7901 M1S1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNE82OC9zMECg{txO MkDGNlQwPDhxN{KgbC=> Ml3kSG1UVw>? NF2zR|dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVnubZNrOjR7OUK5OVg>
MKN-45 M1n3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfiS2RTOTBxNUCvNVAxKM7:TR?= MYSyOE81QC95MjDo M{L1bWROW09? MofQbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NH[yV2IzPDl7Mkm1PC=>
SGC-7901 NEG3TZJHfW6ldHnvckBCe3OjeR?= M3SyOlExNzVyL{GwNEDPxE1? MmewOFghcA>? MUjEUXNQ M1PZbIRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NX;SNGd1OjR7OUK5OVg>
MKN-45 NYDkR4NWTnWwY4Tpc44hSXO|YYm= MXixNE82OC9zMECg{txO Moe5OFghcA>? MX7EUXNQ MYnkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MV:yOFk6Ojl3OB?=
C666-1 M2fN[mN6fG:2b4jpZ4l1gSCDc4PhfS=> M3rMfFIxNThyIN88US=> NVG0fW1qOjRiaB?= MULk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg M4e5dFI1QDV2OEO4
CNE-1 NFHWd5BEgXSxdH;4bYNqfHliQYPzZZk> M4K1UVIxNThyIN88US=> MYWyOEBp M{XW[4Rm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> M1jMdlI1QDV2OEO4
CNE-2 M1jmVWN6fG:2b4jpZ4l1gSCDc4PhfS=> NGjnXIszOC16MDFOwG0> NWnhXVdpOjRiaB?= NWD1U21{\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NUnqO293OjR6NUS4N|g>
C666-1 NV\yUJFOS3m2b4TvfIlkcXS7IFHzd4F6 NX;qU5hqPjBizszN M17O[lch\A>? NVjiSI1l\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> MkTvNlQ5PTR6M{i=
CNE-1 NEjOZXhEgXSxdH;4bYNqfHliQYPzZZk> MXO2NEDPxE1? NWHYOmdFPyCm NXvpfm0x\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NUX4d3p[OjR6NUS4N|g>
SNU-1041 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLlNE01OCEQvF2= M13tWFQ5KGh? MYLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoXKNlQ3QTJ5MEO=
SNU-1041 MlTvSpVv[3Srb36gRZN{[Xl? MUOyNE8{OCEQvF2= MVK0JIg> MojSbY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> NF3jbnMzPDZ7MkewNy=>
SNU-1041 NEXMVFJHfW6ldHnvckBCe3OjeR?= MmH6NE01OCEQvF2= MV60JIg> Ml3WeZAuemWpdXzheIV{KEOKT2FCpIFnfGW{IITy[YF1dWWwdDD3bZRpKGirZ3igZ49v[2WwdILheIlwdnN? MmjmNlQ3QTJ5MEO=
SGC-7901 M3zGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm3Z2VmPTBvMUK1JO69VQ>? MX[yOE81QC95MjDo MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWfLfJo2OjR4N{[zPVQ>
SGC-7901 MoTZRZBweHSxc3nzJGF{e2G7 MlnKNVAxKM7:TR?= MlLoO|IhcA>? NWf2Rm9GcW6mdXPld{BieG:ydH;zbZM> NWToSYp4OjR4N{[zPVQ>
SGC-7901 NHnkVHNHfW6ldHnvckBCe3OjeR?= M{izNlc2NzFyMD:xNlUh|ryP M3z0NVI1NzR6L{eyJIg> NVjubXM3cW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> MkTnNlQ3PzZ|OUS=
LMeC  NUPQWWxzTnWwY4Tpc44hSXO|YYm= M2DydVIxNzVyIN88US=> NGHnNXA1QCCq M1HTOoRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw NXX6cZVkOjR4NU[3OFY>
CMeC-1 M3vKeWNmdGxiVnnhZoltcXS7IFHzd4F6 NVnyRmY1OjBxNUCg{txO NXnuU|dkPDhiaB?= MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2C0O|I1PjV4N{S2
LMeC M{\TS2NmdGxiVnnhZoltcXS7IFHzd4F6 M1fDO|IxNzVyIN88US=> NX;qb3ZxPDhiaB?= NF\HTIpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NYLJcmFHOjR4NU[3OFY>
CMeC-1 NIm0dIxHfW6ldHnvckBCe3OjeR?= Ml\NNlAwPTBizszN NYLpNpJuPDhiaB?= M{TM[4lv\HWlZYOgS|EuWyCjcoLld5Q> MnHwNlQ3PTZ5NE[=
LMeC MXXGeY5kfGmxbjDBd5NigQ>? MWmyNE82OCEQvF2= NYXKXpdRPDhiaB?= MWHpcoR2[2W|IFexMXMh[XK{ZYP0 NWDlSFdSOjR4NU[3OFY>
CMeC-1 NGTuV3JHfW6ldHnvckBCe3OjeR?= M3HOTFIxNzVyIN88US=> Ml3QOFghcA>? Mn7t[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFWwS|QzPDZ3Nke0Oi=>
LMeC MV3GeY5kfGmxbjDBd5NigQ>? MkDvNlAwPTBizszN Mn7COFghcA>? MYnk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWi2dIVNOjR4NU[3OFY>
CMeC-1 MkXqSpVv[3Srb36gRZN{[Xl? MWCyNE82OCEQvF2= Mof6OFghcA>? M4DQeIlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> Mk\vNlQ3PTZ5NE[=
LMeC M2\6S2Z2dmO2aX;uJGF{e2G7 NXjmZYRuOjBxNUCg{txO NIHEWYM1QCCq NGfBeXBqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MmPKNlQ3PTZ5NE[=
OVCAR-3 MlrIR4VtdCCYaXHibYxqfHliQYPzZZk> NWnvTmE3OTBiwsXN MYKxJIg> MkTT[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> M32xelI1PTJyMkK3
OVCAR-3 MVXBdI9xfG:|aYOgRZN{[Xl? M3LzPVExKML3TR?= NIixSYYyKGh? Mk\QdJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh NHzaeoszPDV{MEKyOy=>
OVCAR-3 MW\GeY5kfGmxbjDBd5NigQ>? NHy4eIoyOCEEtV2= NYXBcVQzOSCq NYnSOlZP\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> MV:yOFUzODJ{Nx?=
OVCAR-3 NX7SWIhETnWwY4Tpc44hSXO|YYm= NX3LS2VpOTBiwsXN NXnqUXpHOSCq NXXBc2Rn\G:5bj3y[Yd2dGG2ZYOgUmYu|rqEIHHjeIl3[XSrb36gbY5lfWOnZDDifUBx[WOuaYThfIVt NXftSW1xOjR3MkCyNlc>
OVCAR-3 M{XpPWZ2dmO2aX;uJGF{e2G7 M2XkNFExKML3TR?= MV:xJIg> M3zyWolvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v Mor3NlQ2OjB{Mke=
CF33 MoPSSpVv[3Srb36gRZN{[Xl? MoqyNVAxKM7:TR?= M13IOFI1KGh? NHTVfmVqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NFW0SlkzPDVyM{e4Ni=>
CF33 Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHSfVc3OTBvMUCwJO69VQ>? NXzITpVpOC12IHS= NYC1c3hXcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHXlNVYzPDVyM{e4Ni=>
CF33 NWP2TZR5TnWwY4Tpc44hSXO|YYm= M2nOTFExNTFyMDFOwG0> NFvmWGo1NTJ2IHi= MVfk[YNz\WG|ZYOgZ4VtdHNiaX6geIhmKFNicHjhd4Uh[W6mIHnuZ5Jm[XOnczDj[YxteyCrbjDHNE9IOSCjcoLld5Q> Ml;0NlQ2ODN5OEK=
LNCaP M3K1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXybnB1Oi93L{GwJO69VQ>? M4XrfVk3KGh? NYPBXmd5cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> M1npUlI1Ojl4OUe4
LNCaP M3zmUGFxd3C2b4Ppd{BCe3OjeR?= MoLVNk82NzFyIN88US=> NXGwWWpMQTZiaB?= NEHheotqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> M4\ZPFI1Ojl4OUe4
PC-3  NXmydlRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMVUxKM7:TR?= NIHhOI81QOLCiXi= MlH0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NFG3V4EzPDF{N{i4Ni=>
PC-3  NIfiT3VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3HFPFAuOTByIN88US=> NIHuTVU4OiCq Mo\E[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NWTMR|VPOjRzMke4PFI>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01549743 Completed Healthy Male Volunteers Hanlim Pharm. Co. Ltd. May 9 2012 Phase 1
NCT01881048 Active not recruiting Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer University of Colorado Denver December 8 2009 Early Phase 1
NCT00268476 Recruiting Prostate Cancer Medical Research Council July 8 2005 Phase 2|Phase 3
NCT03084536 Recruiting Breast Cancer|Breast Cancer Female|Cancer of Breast Washington University School of Medicine June 7 2017 Phase 2
NCT02839694 Withdrawn Neoplasm Metastasis|Sarcoma|Neoplasms Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University March 5 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID